Twig Bio Launches $30 Hazel AI Platform, Cutting Biomanufacturing Reviews From Weeks to Minutes
Updated
Updated · SynBioBeta · Jul 21
Twig Bio Launches $30 Hazel AI Platform, Cutting Biomanufacturing Reviews From Weeks to Minutes
1 articles · Updated · SynBioBeta · Jul 21
Summary
Hazel went live on Tuesday as a public AI research platform that generates biomanufacturing and market-viability analyses for about $30 per report.
Twig Bio says the tool compresses work that typically takes weeks and costs thousands into minutes by aggregating biological literature and commercial data into standardized, referenced outputs.
Two report types anchor the platform: Perspective Reports on market, SWOT, literature and IP, and Biofeasibility Reports on pathways, host strains, yield benchmarks and scale-up strategies.
Twig positions Hazel as a way for R&D leaders, CSOs and startup founders to test whether a target is technically buildable and commercially viable before committing lab resources.
The launch reflects a broader push to use specialized AI agents in biotech to de-risk pipeline decisions and widen access to research intelligence once reserved for enterprise budgets.
In a crowded AI biotech field, what is the secret behind Hazel’s claim to turn weeks of complex research into mere minutes?
As AI offers biotech analysis for just $30, can it truly replace the seasoned judgment of human experts in a trillion-dollar industry?
Democratizing Bio-Intelligence: Hazel’s AI Delivers Market & Feasibility Reports in Minutes, Not Weeks
Overview
Hazel, an advanced AI research agent developed by a team of top-tier software engineers and biotech specialists at Twig Bio, officially launched on July 14, 2026. Accessible via askhazel.bio, Hazel is designed to democratize access to high-quality biofeasibility and market intelligence reports for the global scientific community. Its core function is to provide rapid, comprehensive analysis by combining deep data normalization with state-of-the-art infrastructure. This innovative approach streamlines the traditionally time-consuming process of assessing biomanufacturing opportunities, directly addressing the challenge of quickly unifying technical and market insights for scientific leadership.